Ernexa Therapeutics Inc.(ERNA)Earnings, Financials & Key RatiosErnexa Therapeutics Inc. (ERNA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
characterized by a $2.3 million quarterly cash burn and the total absence of revenue, presents an imminent risk of insolvency that outweighs potential upside from its preclinical pipeline.
Ernexa Therapeutics Inc. (ERNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Ernexa Therapeutics Inc. (ERNA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $6.95vs $1.95-256.4% | — |
| Q2 2026 | Mar 13, 2026 | $0.25 | — |
| Q4 2025 | Nov 7, 2025 | $0.15vs $33.00+99.5% | — |
| Q3 2025 | Aug 13, 2025 | $0.61vs $39.00+98.4% | — |
Recent stock market news and headlines for Ernexa Therapeutics Inc. (ERNA)
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027
Key metrics vs top competitors for Ernexa Therapeutics Inc. (ERNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.44 | $2.02M | -0.12 | -100% | — | -686.69% | — | |
| $2.99 | $348.51M | -2.60 | -51.24% | -2056.79% | -58.89% | — | |
| $61.89 | $5.97B | -9.57 | -89.97% | -13856.54% | -30.88% | — | |
| $35.32 | $3.63B | -43.60 | 120.01% | -49.17% | -5.89% | — | |
| $17.84 | $2B | -4.68 | 16.92% | -597.04% | -57.27% | — | |
| $3.65 | $357.36M | -2.03 | 25.39% | -281.59% | -677.39% | — |
Ernexa Therapeutics Inc. (ERNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Ernexa Therapeutics Inc. (ERNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Mar 20, 2026·SEC
Feb 26, 2026·SEC
Get notified when ERNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ernexa Therapeutics Inc. (ERNA) stock FAQ — growth, dividends, profitability & financials explained
Ernexa Therapeutics Inc. (ERNA) saw revenue decline by 100.0% over the past year.
Ernexa Therapeutics Inc. (ERNA) reported a net loss of $11.4M for fiscal year 2025.
Ernexa Therapeutics Inc. (ERNA) has a return on equity (ROE) of -686.7%. Negative ROE indicates the company is unprofitable.
Ernexa Therapeutics Inc. (ERNA) had negative free cash flow of $7.3M in fiscal year 2025, likely due to heavy capital investments.
